GC

Building on its expertise and capabilities in prescription pharmaceuticals,
expanding into medical aesthetics as a new growth area

GC Wellbeing has established a strong presence in the prescription pharmaceutical market, led by its placenta-derived injection Laennec and nutritional injections.
Leveraging its R&D, manufacturing, and quality management capabilities, the company continues to strengthen its core pharmaceutical business while expanding its product portfolio into fillers, skin boosters, and botulinum toxins, positioning medical aesthetics as a new growth driver.
Building on its experience in handling human-derived materials and its established network of hospitals and clinics, GC Wellbeing is broadening its product portfolio and business scope while pursuing sustainable growth in both domestic and international markets.

A biotechnology company advancing medical aesthetics
through botulinum toxin innovation

Inibio develops INIBO, a botulinum toxin type A product manufactured using the company’s proprietary high-purity purification technology. The company is expanding its medical aesthetics portfolio beyond botulinum toxin and pursuing opportunities in both therapeutic and aesthetic applications.
In 2026, Inibio launched INIBO in Peru, marking its entry into the Latin American market. As part of GC Wellbeing’s medical aesthetics portfolio, the company is working to expand its presence in international markets.

A consumer wellness company offering health supplements and functional ingredients for everyday well-being

Earnestree is a health functional food company established as a wholly owned subsidiary of GC Wellbeing in May 2024. Building on GC Wellbeing’s expertise, it develops and markets wellness products for consumers and their families, while distributing functional ingredients. Earnestree aims to make trusted products that support healthier everyday living.

A company specializing in new concept personalized healthcare service
through health promotion service and healthcare systems

Through the "Personalized Health Portal" centered on data and mobile experience, GC Care is actively promoting its IT platform business.
Its goal is to enable anyone to easily receive a checkup anytime, anywhere, quickly self-check symptoms and diseases, and enable convenient self-care in daily life.
In addition, GC Care is expanding the provision of "total healthcare service" that links employees’ checkup results with customized daily care services, and is also expanding the role of "smart care coordinator" for chronic patients who require daily health care.

A leading provider of EMR solutions for healthcare institutions in Korea, advancing digital healthcare through the convergence of medical information and ICT

GC MediAI introduced Korea’s first clinic-focused electronic medical record (EMR) system, U-sarang. Today, the company supports healthcare providers through a broad portfolio that includes EMR solutions, medical distribution, pharmaceutical data and marketing services, and patient-facing platforms.
Building on its extensive healthcare network, GC MediAI is working to unlock the value of medical data through standardization and integration, while advancing AI-powered solutions for the evolving needs of healthcare professionals and patients.

A diagnostics company with more than half a century of experience
serving Korea’s healthcare sector

GC Medical Science Corporation (GCMS) traces its roots to GC’s diagnostics business, launched in 1972. In 1987, it introduced Korea’s first HIV diagnostic reagent, followed by diagnostic reagents for hemorrhagic fever with renal syndrome in 1990.
Today, GCMS applies its immunodiagnostic and molecular diagnostic technologies across a broad portfolio that includes in vitro diagnostic reagents and equipment, blood bags, hemodialysis solutions, blood glucose monitoring systems, and home healthcare products. Through continued research and development, the company is working to expand its presence in the global medical device market.

A POCT specialist advancing health diagnostics for people and pets—
from blood glucose monitoring systems to clinical HbA1c analyzers

Founded in 2005 under the motto, “Bio-IT technology for human, We find the answers from a drop of blood,” GC Medis combines IT and biotechnology to develop point-of-care testing (POCT) solutions for mobile healthcare and in vitro diagnostics.
Its portfolio includes accurate, high-quality blood glucose monitoring systems and multi-analyte POCT systems for HbA1c, inflammatory markers, kidney disease, and blood coagulation markers. The company is also expanding into veterinary POCT to support the health of more animals.

A clinical genomics company advancing diagnosis, prevention,
and research through genomic analysis

GC Genome provides specialized clinical genomic testing to support the diagnosis and prevention of disease. Its services span oncology, rare genetic disorders, prenatal and neonatal care, health screening, and microbiome analysis. Using next-generation sequencing (NGS) and other genomic technologies, GC Genome translates genetic insights into information that can help inform clinical decisions and personalized approaches to care.

Global Clinical Central Lab
Creating Trust | Beyond Expectation, Beyond Borders

GCCL is a clinical trial laboratory providing sample analysis services throughout the clinical development process, from Phase 1 to Phase 4. With full GCLP accreditation, a clinical trial–focused analytical platform, and an integrated sample transportation and logistics system, GCCL delivers reliable, tailored services to support clinical trials in Korea and around the world.

A company dedicated to lifelong wellness for companion animals

Green Vet provides veterinary diagnostic and consulting services through its Reference Lab, including diagnostic imaging through GV Teleradiology Partners, online clinical consultations through the GV Consultation Network, and health screening and management through the GV Care & Solution Center.
Guided by the One Health approach, Green Vet works to support the health of animals, people, and the environment. It takes a whole-life approach to companion animal care and continues to strengthen its research and business capabilities, with the goal of expanding into global markets.

A diagnostics company applying in vitro diagnostic technologies
to human and animal health

Genes Laboratories develops and supplies diagnostic raw materials and products for human and veterinary use, drawing on its expertise in molecular diagnostics. It produces polymerase, a key raw material for PCR diagnostic kits, in-house and has an integrated production system that connects raw material development with product supply.
Building on its R&D capabilities and raw material expertise, the company supplies high-quality diagnostic products and is expanding into areas such as laboratory automation. Genes Laboratories continues to advance diagnostic technologies to help identify a wide range of diseases in people and animals.

A diagnostic company that performs screening
tests on source plasma for plasma-derived products

GC LabTech was established in 2016 in the United States as part of GC’s global strategy for plasma-derived products. The company provides donor screening tests for plasma used in the manufacture of plasma-derived products. GC LabTech is expanding its testing services from normal source plasma to specialty plasma, and it holds certifications and accreditations including CLIA, CAP and ISO.

GC Biopharma’s U.S. Commercial Organization

GC Biopharma USA, Inc. was established in 2018 to support the commercialization of GC Biopharma’s pharmaceutical products in the United States.
The company leads GC Biopharma’s U.S. commercial operations for plasma-derived therapies, including Alyglo® (immune globulin intravenous, human-stwk), 10% Liquid, which received FDA approval in 2023.

The first step towards global advancement of next-generation vaccines
Biotechnology that drives the rapid clinical development of innovative vaccines

As a Seattle-based company, Curevo is currently conducting clinical trials on its next-generation shingles vaccine (CRV101).
Curevo will continue its global clinical development of innovative prophylactic and therapeutic vaccines against infectious diseases to become a next-generation vaccine specialist.
Through collaboration with the world-renowned vaccine organization IDRI (Infectious Disease Research Institute), Curevo is accumulating expertise in vaccine research.

Based on the world’s first commercialization experience of T-cell therapy, GC Lymphotec is deploying an unrivaled business portfolio that spans from next-generation biopharmaceuticals to precision healthcare.

In the advanced cell therapy field, GC Lymphotec continues to develop, manufacture, and sell a range of cell therapy products—including NK cell and stem cell therapies—as well as related culture media.
Its cryopreservative holds a leading share of the Japanese market and is exported to China, Europe, and North America. The company also provides integrated healthcare solutions, including genetic testing-based cancer diagnostics and premium aesthetic services.
GC Lymphotec’s technical capabilities and regulatory credentials are reflected in its 2015 license from Japan’s Ministry of Health, Labour and Welfare to manufacture specified processed cell products, followed by its 2024 clinical laboratory license.

GC DO BRASIL CONSULTORIA DE NEGÓCIOS LTDA :
A local service corporation to expand its exports to South America including Brazil

Expanding GC Biopharma’s business in South America has been established as a key strategic priority.
GC Biopharma do Brasil supports sales growth across the region by providing essential local services for the commercialization of blood products, vaccines, and orphan drugs.

A clinical-stage biotechnology company exploring
new therapeutic possibilities through NK cell-based therapies.

The company develops allogeneic cell therapies using natural killer (NK) cells, focusing on treatments that utilize cells from healthy donors rather than patients' own cells, with the potential to treat multiple patients using donor-derived cells.

Made Scientific is a global cell therapy Contract Development and Manufacturing Organization (CDMO) providing technology transfer, process development, and GMP manufacturing to support programs from clinical through commercial supply.

Made Scientific is a leading U.S.-based clinical- and commercial-stage cell therapy contract development and manufacturing organization (CDMO) specializing in the development, manufacturing, and release of autologous and allogeneic cell therapy products. With GMP facilities located in New Jersey and Pennsylvania, Made Scientific combines the agility of a specialist CDMO with the technical depth to deliver reliable, scalable manufacturing.
Made Scientific is supported by GC Corporation, a long-term strategic owner providing stability, global access, and sustained investment in the business. This partnership reflects a shared commitment to building deliberately, prioritizing scale and quality over short-term outcomes, and positions Made Scientific to advance cell therapy manufacturing with a long-term vision.

A non-profit research foundation discovering and developing innovative medicines through life sciences and artificial intelligence

Established in 1984 with funding from GC Biopharma, following its development of the world’s third hepatitis B vaccine, MOGAM Institute for Biomedical Research is Korea’s first privately established nonprofit research foundation approved by the Ministry of Science and Technology, now the Ministry of Science and ICT.
The institute advances innovative drug discovery through scientific research and artificial intelligence, focusing on next-generation therapeutic platforms—including mRNA, LNP, and antibodies—and disease research.

A scholarship foundation that discovers scientists and provides scholarships
and research funds to contribute to science and technology as well as the overall development of Korea

The Mogam Science Scholarship Foundation is a public foundation established in 2005 with a strong will to advance science and technology. It helps young scientists who will lead Korea's science and technology to reach out to the world, and contribute to the development of Korea. For this purpose, the foundation discovers and provides scholarships and research funds to science students who will become the main driving force behind the development of science and technology in Korea.

The foundation operates scholarship programs for North Korean defector students, helping them realize their passion for learning and hope for the future, and grow into leaders in the era of unification.

As a public interest foundation established in 2009, the Future Foundation of Korea operates scholarship programs to help North Korean refugee students grow into leaders in the era of unification with a passion for learning and hope for the future. Recipients of the Scholarship will grow into members of a sharing community that ensures equal rights and bright future. Through this, the foundation helps North Korean refugees settle down in South Korea in terms of living, health, study, job, and norms, and is working together to create a happy future as a good citizen in Korean society.

A clinical laboratory advancing diagnostics
through innovation and specialized testing

Since its establishment in 1982, GC Labs has supported accurate diagnosis and treatment as a specialized clinical laboratory testing provider. Drawing on advanced automation systems and experienced professionals, it performs approximately 5,000 types of tests quickly and accurately, supporting healthcare providers with laboratory medicine and pathology testing.
GC Labs is committed to maintaining the quality and reliability of its results through certifications including ISO 9001, ISO 14001, and ISO 15189, as well as participation in international accreditation and proficiency-testing programs such as CAP and G-EQUAS.

A functional medicine center supporting healthier lives
through early detection and personalized care

Established in Seocho in 1991, GC i-MED provides comprehensive health screenings and functional medicine care tailored to each individual. Combining advanced screening systems with the expertise of its medical professionals, GC i-MED helps detect health concerns early and supports patients with follow-up care and ongoing health management.
GC i-MED operates clinics in Gangnam, Gangbuk, and Seoul Forest, offering screening and medical services tailored to each person’s health needs.

The only bioengineering construction company in Korea that provides
total services ranging from consulting to design, construction,
verification, and maintenance

Since its establishment in 2001, GCEM has been the only bioengineering & construction company in Korea. Excellent pharmaceutical manufacturing facilities and research laboratories are essential infrastructure for public health. However, no one else has attempted to build these facilities. But GCEM has steadily paved the way to dedicate itself to public health. GCEM is a customer-centered company that creates customer value through the best quality, safe construction, and thorough follow-up management from design to construction, verification, and maintenance with its best technology and services. Not satisfied with this, GCEM will create values ​​that exceed the needs of customers in all fields of bioengineering through business diversification with the goal of becoming a "leader in the bio and GMP construction field".

A company that stably supplies high-quality fertilized eggs
for vaccines, which are produced in-house

GC Invacfarm has established the nation's best isolation and quarantine system, operates a poultry farm that produces fertilized eggs under strict quality control standards, and has a hatchery that hatches fertilized eggs to a level suitable for vaccine production. It contributes to the growth and development of GC Biopharma flu vaccine by ensuring a stable supply of high-quality fertilized eggs for the vaccine.